These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18167532)

  • 1. Quantitative analysis on the characteristics of targets with FDA approved drugs.
    Sakharkar MK; Li P; Zhong Z; Sakharkar KR
    Int J Biol Sci; 2007 Dec; 4(1):15-22. PubMed ID: 18167532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network analysis of FDA approved drugs and their targets.
    Ma'ayan A; Jenkins SL; Goldfarb J; Iyengar R
    Mt Sinai J Med; 2007 Apr; 74(1):27-32. PubMed ID: 17516560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic analysis of FDA-approved anticancer drugs.
    Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015.
    Lin HH; Zhang LL; Yan R; Lu JJ; Hu Y
    Sci Rep; 2017 Sep; 7(1):12230. PubMed ID: 28947756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
    Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F
    PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From idea to market: the drug approval process.
    Lipsky MS; Sharp LK
    J Am Board Fam Pract; 2001; 14(5):362-7. PubMed ID: 11572541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inadequacy of the reductionist approach in discovering new therapeutic agents against complex diseases.
    Duval MX
    Exp Biol Med (Maywood); 2018 Aug; 243(12):1004-1013. PubMed ID: 30089398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Publication of clinical trials supporting successful new drug applications: a literature analysis.
    Lee K; Bacchetti P; Sim I
    PLoS Med; 2008 Sep; 5(9):e191. PubMed ID: 18816163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic agents marketed in 1995.
    Hussar DA
    Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
    Pease AM; Krumholz HM; Downing NS; Aminawung JA; Shah ND; Ross JS
    BMJ; 2017 May; 357():j1680. PubMed ID: 28468750
    [No Abstract]   [Full Text] [Related]  

  • 19. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 Apr; 97(4):12-6. PubMed ID: 8008381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.